Blog
Old drugs, new tricks
Unexpected discoveries in the various stages of drug development are still rather the norm than the exception. Unexpected drug effects are not limited to only adverse drug reactions. Some effects turn out to be beneficial, or even to be an unexpected breakthrough in the treatment of another disease.
Pragmatismus gefragt – Herausforderungen und Chancen für die klinische Forschung im Zeitalter der frühen Nutzenbewertung in Deutschland
In einer Hinsicht sind sich Interessenvertreter der Industrie und der Kostenträger einig – das Arzneimittel-Neuordnungs-Gesetz habe sein Ziel verfehlt. Doch was haben wir gelernt?
Listen to your eye
The eye is not only our window to the world. Reversing perspectives, it also serves as a valuable access point to examine the human body inside out. Indeed, a look through the pupil provides insight into a patient’s overall health status!
Why breakthrough in Alzheimer’s disease is still far away
We have a target and we have a spreading pattern – so why don’t we have a therapy yet? And why are we consciously ignoring the few reliable findings from preclinical and translational studies?
Game changer for the fight against cancer?
Although not yet brought into daily clinical routine, new screening methods and individualized pharmacological treatment concepts are under evaluation and show promising first results. Three recent findings describe the advances in research for breast, prostate and pancreatic cancer.
Design und Auswertung einer Medizinproduktestudie – nur die Variation einer Arzneimittelstudie?
Die Medizinproduktestudie als Variation der Arzneimittelstudie? Im Detail zeigen sich Unterschiede, die sich grundlegend auf Design und Auswertung einer Medizinproduktstudie auswirken können.